{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:36:05Z","timestamp":1793050565623,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Verona","id":[{"id":"https:\/\/ror.org\/039bp8j42","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00198-026-08113-3","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:15:46Z","timestamp":1781756146000},"page":"2343-2354","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Romosozumab does not improve volumetric bone mineral density at distal radius but is associated with early changes in bone strength: a prospective study"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4597-2562","authenticated-orcid":false,"given":"Mariana","family":"Diz-Lopes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina Fanti","family":"Rovetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pollastri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Mastropaolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Somma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Tugnolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Pasetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Benini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Fassio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ombretta","family":"Viapiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Grendene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Mozzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Adami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"8113_CR1","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40618-024-02469-1","volume":"48","author":"VN Makinen","year":"2025","unstructured":"Makinen VN, Solling AS, McClung M, Langdahl BL (2025) Romosozumab for the treatment of osteoporosis - a systematic review. J Endocrinol Invest 48:547\u2013572","journal-title":"J Endocrinol Invest"},{"key":"8113_CR2","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543","journal-title":"N Engl J Med"},{"key":"8113_CR3","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u20131427","journal-title":"N Engl J Med"},{"key":"8113_CR4","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412\u2013420","journal-title":"N Engl J Med"},{"key":"8113_CR5","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1359\/jbmr.090411","volume":"24","author":"C Lin","year":"2009","unstructured":"Lin C, Jiang X, Dai Z, Guo X, Weng T, Wang J, Li Y, Feng G, Gao X, He L (2009) Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt\/beta-catenin signaling. J Bone Miner Res 24:1651\u20131661","journal-title":"J Bone Miner Res"},{"key":"8113_CR6","doi-asserted-by":"publisher","first-page":"16744","DOI":"10.1074\/jbc.M114.628313","volume":"290","author":"JM Spatz","year":"2015","unstructured":"Spatz JM, Wein MN, Gooi JH et al (2015) The Wnt inhibitor sclerostin is up-regulated by mechanical unloading in osteocytes in vitro. J Biol Chem 290:16744\u201316758","journal-title":"J Biol Chem"},{"key":"8113_CR7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2220\/biomedres.41.279","volume":"41","author":"T Yamamoto","year":"2020","unstructured":"Yamamoto T, Ikegame M, Hirayama J et al (2020) Expression of sclerostin in the regenerating scales of goldfish and its increase under microgravity during space flight. Biomed Res 41:279\u2013288","journal-title":"Biomed Res"},{"key":"8113_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41526-022-00194-8","volume":"8","author":"J Man","year":"2022","unstructured":"Man J, Graham T, Squires-Donelly G, Laslett AL (2022) The effects of microgravity on bone structure and function. NPJ Microgravity 8:9","journal-title":"NPJ Microgravity"},{"key":"8113_CR9","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.cmet.2007.05.001","volume":"5","author":"S Tatsumi","year":"2007","unstructured":"Tatsumi S, Ishii K, Amizuka N, Li M, Kobayashi T, Kohno K, Ito M, Takeshita S, Ikeda K (2007) Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab 5:464\u2013475","journal-title":"Cell Metab"},{"key":"8113_CR10","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00198-021-05999-z","volume":"32","author":"JP van den Bergh","year":"2021","unstructured":"van den Bergh JP, Szulc P, Cheung AM, Bouxsein M, Engelke K, Chapurlat R (2021) The clinical application of high-resolution peripheral computed tomography (HR-pQCT) in adults: state of the art and future directions. Osteoporos Int 32:1465\u20131485","journal-title":"Osteoporos Int"},{"key":"8113_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/S2213-8587(18)30308-5","volume":"7","author":"EJ Samelson","year":"2019","unstructured":"Samelson EJ, Broe KE, Xu H et al (2019) Cortical and trabecular bone microarchitecture as an independent predictor of incident fracture risk in older women and men in the Bone Microarchitecture International Consortium (BoMIC): a prospective study. Lancet Diabetes Endocrinol 7:34\u201343","journal-title":"Lancet Diabetes Endocrinol"},{"key":"8113_CR12","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1002\/jbmr.1784","volume":"28","author":"S Hansen","year":"2013","unstructured":"Hansen S, Hauge EM, Beck Jensen JE, Brixen K (2013) Differing effects of PTH 1-34, PTH 1-84, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis: an 18-month open-labeled observational study using HR-pQCT. J Bone Miner Res 28:736\u2013745","journal-title":"J Bone Miner Res"},{"key":"8113_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/jbmr.2315","volume":"30","author":"JN Tsai","year":"2015","unstructured":"Tsai JN, Uihlein AV, Burnett-Bowie SA, Neer RM, Zhu Y, Derrico N, Lee H, Bouxsein ML, Leder BZ (2015) Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT study. J Bone Miner Res 30:39\u201345","journal-title":"J Bone Miner Res"},{"key":"8113_CR14","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1002\/jbmr.3735","volume":"34","author":"P Chavassieux","year":"2019","unstructured":"Chavassieux P, Chapurlat R, Portero-Muzy N, Roux JP, Garcia P, Brown JP, Libanati C, Boyce RW, Wang A, Grauer A (2019) Bone-forming and antiresorptive effects of romosozumab in postmenopausal women with osteoporosis: bone histomorphometry and microcomputed tomography analysis after 2 and 12 months of treatment. J Bone Miner Res 34:1597\u20131608","journal-title":"J Bone Miner Res"},{"key":"8113_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2026.101902","volume":"28","author":"MB Zanchetta","year":"2026","unstructured":"Zanchetta MB, Gonzalez-Pernas M, Jerkovich F, Pingel J, Schwartz N, Erdociain L, Zanchetta JR (2026) Assessing cortical bone changes with Romosozumab after one year: Insights from an exploratory HR-pQCT study. Bone Rep 28:101902","journal-title":"Bone Rep"},{"key":"8113_CR16","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/S8756-3282(02)00736-6","volume":"30","author":"W Pistoia","year":"2002","unstructured":"Pistoia W, van Rietbergen B, Lochmuller EM, Lill CA, Eckstein F, Ruegsegger P (2002) Estimation of distal radius failure load with micro-finite element analysis models based on three-dimensional peripheral quantitative computed tomography images. Bone 30:842\u2013848","journal-title":"Bone"},{"key":"8113_CR17","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/jbmr.3452","volume":"33","author":"MR McClung","year":"2018","unstructured":"McClung MR, Brown JP, Diez-Perez A et al (2018) Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study. J Bone Miner Res 33:1397\u20131406","journal-title":"J Bone Miner Res"},{"key":"8113_CR18","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/jbmr.3036","volume":"32","author":"MS Ominsky","year":"2017","unstructured":"Ominsky MS, Boyd SK, Varela A et al (2017) Romosozumab improves bone mass and strength while maintaining bone quality in ovariectomized cynomolgus monkeys. J Bone Miner Res 32:788\u2013801","journal-title":"J Bone Miner Res"},{"key":"8113_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.bone.2010.09.009","volume":"48","author":"X Tian","year":"2011","unstructured":"Tian X, Jee WS, Li X, Paszty C, Ke HZ (2011) Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model. Bone 48:197\u2013201","journal-title":"Bone"},{"key":"8113_CR20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3389\/fendo.2015.00054","volume":"6","author":"T Sugiyama","year":"2015","unstructured":"Sugiyama T, Torio T, Miyajima T, Kim YT, Oda H (2015) Romosozumab and blosozumab: alternative drugs of mechanical strain-related stimulus toward a cure for osteoporosis. Front Endocrinol (Lausanne) 6:54","journal-title":"Front Endocrinol (Lausanne)"},{"key":"8113_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/jbmr.173","volume":"26","author":"D Padhi","year":"2011","unstructured":"Padhi D, Jang G, Stouch B, Fang L, Posvar E (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19\u201326","journal-title":"J Bone Miner Res"},{"key":"8113_CR22","first-page":"R324","volume":"274","author":"MH Lafage-Proust","year":"1998","unstructured":"Lafage-Proust MH, Collet P, Dubost JM, Laroche N, Alexandre C, Vico L (1998) Space-related bone mineral redistribution and lack of bone mass recovery after reambulation in young rats. Am J Physiol 274:R324-334","journal-title":"Am J Physiol"},{"key":"8113_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2022.101635","volume":"17","author":"H Inose","year":"2022","unstructured":"Inose H, Kato T, Tomizawa S, Ariga A, Motoyoshi T, Fukushima K, Takahashi K, Yoshii T, Okawa A (2022) Impact of romosozumab on serum calcium concentration and factors predicting the fluctuations in calcium concentration upon romosozumab administration: a multicenter retrospective study. Bone Rep 17:101635","journal-title":"Bone Rep"},{"key":"8113_CR24","doi-asserted-by":"publisher","first-page":"ziae016","DOI":"10.1093\/jbmrpl\/ziae016","volume":"8","author":"G Adami","year":"2024","unstructured":"Adami G, Pedrollo E, Rossini M, Fassio A, Braga V, Pasetto E, Pollastri F, Benini C, Viapiana O, Gatti D (2024) Romosozumab added to ongoing denosumab in postmenopausal osteoporosis, a prospective observational study. JBMR Plus 8:ziae016","journal-title":"JBMR Plus"},{"key":"8113_CR25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1359\/jbmr.0809010","volume":"24","author":"JP Brown","year":"2009","unstructured":"Brown JP, Prince RL, Deal C et al (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24:153\u2013161","journal-title":"J Bone Miner Res"},{"key":"8113_CR26","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/jbmr\/zjae112","volume":"39","author":"FH Glorieux","year":"2024","unstructured":"Glorieux FH, Langdahl B, Chapurlat R et al (2024) Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid study. J Bone Miner Res 39:1215\u20131228","journal-title":"J Bone Miner Res"},{"key":"8113_CR27","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.bone.2015.07.036","volume":"81","author":"C Graeff","year":"2015","unstructured":"Graeff C, Campbell GM, Pena J, Borggrefe J, Padhi D, Kaufman A, Chang S, Libanati C, Gluer CC (2015) Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis. Bone 81:364\u2013369","journal-title":"Bone"},{"key":"8113_CR28","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s00198-020-05438-5","volume":"31","author":"DE Whittier","year":"2020","unstructured":"Whittier DE, Boyd SK, Burghardt AJ, Paccou J, Ghasem-Zadeh A, Chapurlat R, Engelke K, Bouxsein ML (2020) Guidelines for the assessment of bone density and microarchitecture in vivo using high-resolution peripheral quantitative computed tomography. Osteoporos Int 31:1607\u20131627","journal-title":"Osteoporos Int"},{"key":"8113_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12880-018-0255-7","volume":"18","author":"M Peters","year":"2018","unstructured":"Peters M, de Jong J, Scharmga A et al (2018) An automated algorithm for the detection of cortical interruptions and its underlying loss of trabecular bone; a reproducibility study. BMC Med Imaging 18:13","journal-title":"BMC Med Imaging"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08113-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08113-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08113-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:01:35Z","timestamp":1793048495000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08113-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["8113"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-08113-3","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"18 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted according to the protocol REUMABANK (1483CESC) approved by our local Ethics Committee in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was collected for each participant.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients provided consent for publication of anonymized data.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Giovanni Adami has received advisory board honoraria, consultancy fees, and\/or speaker fees from Theramex, UCB, Lilly, Galapagos, Fresenius Kabi, Amgen, BMS, Abiogen, and Pfizer. Davide Gatti has received advisory board honoraria, consultancy fees, and\/or speaker fees from Accord Health Care, Abiogen, Amgen, Eli Lilly, Mereo, Neopharmed-Gentili, and UCB. Angelo Fassio reports personal fees from Abiogen, Novartis, and Neopharmed. Maurizio Rossini reports advisory board honoraria, consultancy fees, and\/or speaker fees from AbbVie, Eli Lilly, ItalFarmaco, Neopharmed-Gentili, Theramex, Janssen-Cilag, and UCB, outside the submitted work. Ombretta Viapiana has received advisory board honoraria and speaker fees from Gilead, Fresenius Kabi, Biogen, Eli Lilly, UCB, Abbvie, MSD, and BMS. The other authors have disclosed no conflicts of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}